Shanghai Shyndec Pharmaceutical 将来の成長

Future 基準チェック /16

Shanghai Shyndec Pharmaceutical利益と収益がそれぞれ年間16%と7.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に10.3% 16.3%なると予測されています。

主要情報

16.0%

収益成長率

16.3%

EPS成長率

Pharmaceuticals 収益成長	18.8%
収益成長率	7.6%
将来の株主資本利益率	10.3%
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

XSSC:600420 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	13,705	1,557	N/A	2,784	2
12/31/2025	12,876	1,377	N/A	2,490	2
12/31/2024	12,024	1,173	N/A	2,217	1
9/30/2024	11,501	1,082	2,036	2,300	N/A
6/30/2024	11,585	1,065	2,332	2,626	N/A
3/31/2024	11,776	844	1,880	2,162	N/A
12/31/2023	12,070	692	1,363	1,720	N/A
9/30/2023	12,402	765	2,022	2,336	N/A
6/30/2023	13,017	748	2,186	2,500	N/A
3/31/2023	13,132	729	2,402	2,708	N/A
12/31/2022	12,959	628	2,548	2,856	N/A
9/30/2022	12,954	363	1,924	2,273	N/A
6/30/2022	12,700	367	2,115	2,503	N/A
3/31/2022	13,260	425	1,536	1,991	N/A
12/31/2021	13,945	568	1,158	1,680	N/A
9/30/2021	13,903	649	1,148	1,712	N/A
6/30/2021	13,977	748	966	1,524	N/A
3/31/2021	13,182	734	1,470	2,002	N/A
12/31/2020	12,556	649	1,182	1,560	N/A
9/30/2020	12,538	713	153	496	N/A
6/30/2020	12,156	611	-72	371	N/A
3/31/2020	12,328	607	293	685	N/A
12/31/2019	12,199	656	866	1,270	N/A
9/30/2019	11,860	703	2,418	2,839	N/A
6/30/2019	11,723	667	2,389	2,779	N/A
3/31/2019	11,386	717	1,270	1,669	N/A
12/31/2018	11,321	706	1,270	1,669	N/A
9/30/2018	10,416	647	2,220	2,530	N/A
6/30/2018	9,791	569	N/A	2,411	N/A
3/31/2018	9,260	530	N/A	2,565	N/A
12/31/2017	8,518	516	N/A	2,315	N/A
9/30/2017	9,086	539	N/A	1,050	N/A
6/30/2017	9,124	544	N/A	869	N/A
3/31/2017	9,324	534	N/A	654	N/A
12/31/2016	9,126	477	N/A	839	N/A
9/30/2016	13,514	773	N/A	1,898	N/A
6/30/2016	12,126	697	N/A	1,821	N/A
3/31/2016	10,388	580	N/A	1,912	N/A
12/31/2015	8,988	530	N/A	1,666	N/A
9/30/2015	2,829	206	N/A	254	N/A
6/30/2015	2,820	211	N/A	50	N/A
3/31/2015	2,882	203	N/A	202	N/A
12/31/2014	2,749	190	N/A	259	N/A
9/30/2014	2,492	169	N/A	292	N/A
6/30/2014	2,442	159	N/A	386	N/A
3/31/2014	2,317	137	N/A	129	N/A
12/31/2013	2,350	133	N/A	207	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 600420の予測収益成長率 (年間16% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 600420の収益 ( 16% ) CN市場 ( 26.2% ) よりも低い成長が予測されています。

高成長収益: 600420の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 600420の収益 ( 7.6% ) CN市場 ( 13.9% ) よりも低い成長が予測されています。

高い収益成長: 600420の収益 ( 7.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 600420の自己資本利益率は、3年後には低くなると予測されています ( 10.3 %)。

Shanghai Shyndec Pharmaceutical 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.13 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.15 in 1Q 2023)

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.076 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in FY 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.62 in FY 2019)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.47

New 90-day low: CN¥9.01

New 90-day low: CN¥9.42

New 90-day high: CN¥10.68

Third quarter earnings released

New 90-day low: CN¥9.49

First half earnings released

New 90-day high - CN¥10.64

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘